Increase of regulatory T cells and the ratio of specific IgE to total IgE are candidates for response monitoring or prognostic biomarkers in 2-year sublingual immunotherapy (SLIT) for Japanese cedar pollinosis

Clinical Immunology

Volumn 139, Issue 1, 2011, Pages 65-74

  Fujimura, Takashi ^a,c   Yonekura, Syuji ^a   Horiguchi, Shigetoshi ^a   Taniguchi, Yuriko ^a   Saito, Akemi ^b   Yasueda, Hiroshi ^b   Inamine, Ayako ^a   Nakayama, Toshinori ^a   Takemori, Toshitada ^c   Taniguchi, Masaru ^c   Sakaguchi, Masahiro ^d   Okamoto, Yoshitaka ^a  

^a CHIBA UNIVERSITY   (Japan)

^b SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^c INST OF PHYS AND CHEMICAL RESEARCH   (Japan)

^d AZABU UNIVERSITY   (Japan)

Author keywords

Allergic rhinitis; Biomarker; Immunotherapy; Japanese cedar pollinosis; Regulatory T cell; Sublingual immunotherapy

Indexed keywords

IMMUNOGLOBULIN E; PLACEBO; BIOLOGICAL MARKER; CYTOKINE; PLANT EXTRACT;

ADULT; ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; IMMUNOTHERAPY; JAPANESE CEDAR; MAJOR CLINICAL STUDY; MALE; POLLEN ALLERGY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SUBLINGUAL IMMUNOTHERAPY; THERAPY EFFECT; TREATMENT RESPONSE; UPREGULATION; ADOLESCENT; AGED; ANTIBODY SPECIFICITY; BLOOD; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PHYSIOLOGY; POLLEN; RHINITIS, ALLERGIC, SEASONAL; SUBLINGUAL DRUG ADMINISTRATION; YOUNG ADULT;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; AGED; ANTIBODY SPECIFICITY; BIOLOGICAL MARKERS; CRYPTOMERIA; CYTOKINES; DOUBLE-BLIND METHOD; FEMALE; GENE EXPRESSION REGULATION; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PLANT EXTRACTS; POLLEN; RHINITIS, ALLERGIC, SEASONAL; T-LYMPHOCYTES, REGULATORY; YOUNG ADULT;

EID: 79953007576     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2010.12.022     Document Type: Article

References (24)

1. Baba K., Nakae K. Epidemiology of nasal allergy through Japan in 2008. Prog. Med. 2008, 28:2001-2012. (In Japanese).
2. Yasueda H., Akiyama K., Maeda Y., Hayakawa T., Kaneko F., Hasegawa M., et al. An enzyme-linked immunosorbent assay (ELISA) for the quantitation of sugi pollen and Dermatophagoides mite allergens and its application for standardization of allergen extracts. Arerugi 1991, 40:1218-1225. (In Japanese).
3. Horiguchi S., Okamoto Y., Yonekura S., Okawa T., Yamamoto H., Kunii N., et al. A randomized controlled trial of sublingual immunotherapy for Japanese cedar pollinosis. Int. Arch. Allergy Immunol. 2008, 146:76-84.
4. Okubo K., Gotoh M., Fujieda S., Okano M., Yoshida H., Morikawa H., et al. A randomized double-blind comparative study of sublingual immunotherapy for cedar pollinosis. Allergol. Int. 2008, 57:265-275.
5. Yamanaka K., Yuta A., Kakeda M., Sasaki R., Kitagawa H., Gabazza E., et al. Induction of IL-10-producing regulatory T cells with TCR diversity by epitope-specific immunotherapy in pollinosis. J. Allergy Clin. Immunol. 2009, 124:842-845. e7.
6. Fujimura T., Yonekura S., Taniguchi Y., Horiguchi S., Saito A., Yasueda H., et al. The induced regulatory T-cell level, defined as the proportion of IL10+Foxp3+ cells among CD25+CD4+ leukocytes, is an available response monitoring biomarker for sublingual immunotherapy: a preliminary report. Int. Arch. Allergy Immunol. 2010, 153:378-387.
7. Practical Guideline for the Management of Allergic Rhinitis in Japan-Perennial rhinitis and Pollinosis-2005 Edition (The fifth revision) 2005, Life Science Publishing Co. Ltd., Tokyo.
8. Okubo K., Takizawa R., Gotoh M., Okuda M. Experience of specific immunotherapy with standardized Japanese cedar pollen extract. Arerugi 2001, 50:520-527. (In Japanese).
9. Okuda M., Ohkubo K., Goto M., Okamoto H., Konno A., Baba K., et al. Comparative study of two Japanese rhinoconjunctivitis quality-of-life questionnaires. Acta Otolaryngol. 2005, 125:736-744.
10. Trotti A., Colevas A.D., Setser A., Rusch V., Jaques D., Budach V., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin. Radiat. Oncol. 2003, 13:176-181.
11. Yasueda H., Saito A., Sakaguchi M., Ide T., Saito S., Taniguchi Y., et al. Identification and characterization of a group 2 conifer pollen allergen from Chamaecyparis obtusa, a homologue of Cry j 2 from Cryptomeria japonica. Clin. Exp. Allergy 2000, 30:546-550.
12. Calderon M., Brandt T. Treatment of grass pollen allergy: focus on a standardized grass allergen extract-Grazax. Ther. Clin. Risk Manage. 2008, 4:1255-1260.
13. Durham S.R., Yang W.H., Pedersen M.R., Johansen N., Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2006, 117:802-809.
14. Okamoto Y., Horiguti S., Yamamoto H., Yonekura S., Hanazawa T. Present situation of cedar pollinosis in Japan and its immune responces. Allergol. Int. 2009, 58:155-162.
15. Wachholz P.A., Nouri-Aria K.T., Wilson D.R., Walker S.M., Verhoef A., Till S.J., et al. Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology 2002, 105:56-62.
16. Rolinck-Werninghaus C., Kopp M., Liebke C., Lange J., Wahn U., Niggemann B. Lack of detectable alterations in immune responses during sublingual immunotherapy in children with seasonal allergic rhinoconjunctivitis to grass pollen. Int. Arch. Allergy Immunol. 2005, 136:134-141.
17. Moingeon P., Batard T., Fadel R., Frati F., Sieber J., Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006, 61:151-165.
18. Ciprandi G., Marseglia G.L., Tosca M.A. Allergen-specific immunotherapy: an update on immunological mechanisms of action. Monaldi Arch. Chest Dis. 2006, 65:34-37.
19. Di Lorenzo G., Mansueto P., Pacor M.L., Rizzo M., Castello F., Martinelli N., et al. Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy. J. Allergy Clin. Immunol. 2009, 123:1103-1110. 1110 e1-4.
20. Gri G., Piconese S., Frossi B., Manfroi V., Merluzzi S., Tripodo C., et al. CD4+CD25+ regulatory T cells suppress mast cell degranulation and allergic responses through OX40-OX40L interaction. Immunity 2008, 29:771-781.
21. Ohkawara Y., Lim K.G., Xing Z., Glibetic M., Nakano K., Dolovich J., et al. CD40 expression by human peripheral blood eosinophils. J. Clin. Invest. 1996, 97:1761-1766.
22. Radulovic S., Jacobson M.R., Durham S.R., Nouri-Aria K.T. Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J. Allergy Clin. Immunol. 2008, 121:1467-1472. e1.
23. Asai K., Foley S.C., Sumi Y., Yamauchi Y., Takeda N., Desrosiers M., et al. Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy increases CD4+CD25+ T cells in the nasal mucosa of subjects with allergic rhinitis. Allergol. Int. 2008, 57:377-381.
24. Devillier P., Le Gall M., Horak F. The allergen challenge chamber: a valuable tool for optimizing the clinical development of pollen immunotherapy. Allergy 2011, 66:163-169.